Who owns AgomAb Therapeutics NV?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AGMB from SEC Form 13F filings across 39 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 39 institutions disclosed 28.1M shares of AgomAb Therapeutics NV worth $310.5M — about 5191% of shares outstanding; the largest disclosed holder is EQT Fund Management S.a r.l.. Source: SEC Form 13F filings, parsed by EvidInvest.
39
13F holders
$310.5M
value, 2026 filers
5191%
of shares outstanding (28.1M sh)
12
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of AGMB's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | EQT Fund Management S.a r.l. | 5.1M | $57.1M | 6.0% | 950.2% | 0.0% |
| 2 | Sanofi | 2.8M | $30.9M | 4.9% | 514.3% | 0.0% |
| 3 | Cormorant Asset Management, LP | 2.5M | $27.4M | 1.8% | 455.6% | 0.0% |
| 4 | Pfizer Inc | 2.2M | $22.6M | 13.8% | 397.5% | +2768.3% |
| 5 | TCG Crossover Management, LLC | 1.8M | $20.2M | 0.6% | 336.5% | -11.3% |
| 6 | Nantahala Capital Management, LLC | 1.7M | $19.4M | 0.6% | 323% | +11.5% |
| 7 | Redmile Group, LLC | 1.7M | $19.3M | 1.4% | 321.6% | -36.3% |
| 8 | FEDERATED HERMES, INC. | 1.6M | $17.9M | 0.0% | 298.3% | -0.2% |
| 9 | Casdin Capital, LLC | 1.6M | $17.2M | 0.7% | 286.4% | 0.0% |
| 10 | ANDERA PARTNERS | 1.5M | $17.1M | 9.7% | 284.4% | 0.0% |
| 11 | FMR LLC | 1.5M | $16.2M | 0.0% | 269.6% | 0.0% |
| 12 | Aberdeen Group plc | 1.2M | $13.7M | 0.0% | 228.7% | +46.1% |
| 13 | PERCEPTIVE ADVISORS LLC | 600,000 | $6.7M | 0.1% | 110.9% | 0.0% |
| 14 | SAMSARA BIOCAPITAL, LLC | 594,749 | $6.6M | 0.6% | 109.9% | -0.9% |
| 15 | Siren, L.L.C. | 411,250 | $4.6M | 0.1% | 76% | 0.0% |
| 16 | Woodline Partners LPNEW | 251,292 | $2.8M | 0.0% | 46.4% | new |
| 17 | Integral Health Asset Management, LLCNEW | 235,000 | $2.6M | 0.2% | 43.4% | new |
| 18 | SEVEN GRAND MANAGERS, LLC | 200,000 | $2.2M | 0.1% | 37% | +320.2% |
| 19 | TWO SIGMA INVESTMENTS, LP | 91,243 | $1.0M | 0.0% | 16.9% | +404.9% |
| 20 | Point72 Asset Management, L.P.NEW | 67,032 | $744,055 | 0.0% | 12.4% | new |
| 21 | ALPS ADVISORS INC | 64,778 | $719,036 | 0.0% | 12% | +29.6% |
| 22 | JANE STREET GROUP, LLCNEW | 59,208 | $657,209 | 0.0% | 10.9% | new |
| 23 | Quadrature Capital Ltd | 54,424 | $604,106 | 0.0% | 10.1% | +166.0% |
| 24 | UBS Group AG | 51,516 | $571,828 | 0.0% | 9.5% | +2320.9% |
| 25 | Bellevue Group AG | 34,836 | $386,680 | 0.0% | 6.4% | -29.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.